The incorporation of the anti-EGFR nanobody significantly improved cellular uptake and cytotoxicity in EGFR-overexpressing triple-negative breast cancer cells, enhancing tumor targeting and treatment efficacy in an orthotopic xenograft model (Figure 6) [102]. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.